Zilovertamab is a first-in-class humanized monoclonal antibody that binds to ROR1. Zilovertamab has been undergoing clinical trials in combination with ibrutinib for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.